Advertisement

Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study

Published:November 28, 2022DOI:https://doi.org/10.1016/j.jpurol.2022.11.020

      Summary

      Background

      Neurogenic detrusor overactivity (NDO) can damage the upper urinary tract leading to chronic renal impairment. Antimuscarinic therapy is used to improve urinary incontinence and protect the upper urinary tract in patients with NDO.

      Objective

      This study investigated safety and efficacy of fesoterodine, a muscarinic receptor antagonist, in 6‒<18-year-old patients with NDO (NCT01557244).

      Study design

      This open-label phase 3 study included 2 pediatric cohorts. Patients in Cohort 1 (bodyweight >25 kg) were randomized to fesoterodine 4 or 8 mg extended-release tablets or oxybutynin XL tablets administered over the 12-week active comparator-controlled phase. The safety extension phase evaluated fesoterodine 4 and 8 mg for a further 12 weeks, with patients in the oxybutynin arm allocated to fesoterodine 4 or 8 mg. Patients in Cohort 2 (bodyweight ≤25 kg) were randomized to fesoterodine 2 or 4 mg extended-release beads-in-capsule (BIC) administered over a 12-week efficacy phase and 12-week safety extension phase. Patients with stable neurologic disease and clinically or urodynamically proven NDO were included. The primary endpoint was change from baseline to Week 12 in maximum cystometric bladder capacity (MCC). Secondary efficacy endpoints included detrusor pressure at maximum bladder capacity, bladder volume at first involuntary detrusor contraction, bladder compliance, and incontinence episodes. Safety endpoints included adverse event incidence, and specific assessments of cognition, behavior and vision. The pharmacokinetics of 5-hydroxymethyl tolterodine (5-HMT; fesoterodine’s active metabolite) was determined using population-pharmacokinetic analysis.

      Results

      In Cohort 1 (n = 124), fesoterodine 4 and 8 mg treatment resulted in significant increases from baseline in the primary endpoint of MCC at Week 12. In Cohort 2 (n = 57), fesoterodine 2 and 4 mg BIC treatment resulted in improvements in MCC from baseline. Fesoterodine 4 and 8 mg and fesoterodine 4 mg BIC led to improvements in some secondary efficacy endpoints. The most common treatment-related adverse reactions were gastrointestinal effects, such as dry mouth, which occurred more frequently with oxybutynin than fesoterodine. No detrimental effects on visual accommodation or acuity, or on cognitive function or behavior were observed.

      Discussion

      These safety and efficacy results are consistent with limited published data on fesoterodine treatment in pediatric populations with overactive bladder or NDO. Study limitations include the lack of placebo control and the small sample size, which limits the ability to make formal efficacy comparisons and detect rare adverse reactions.

      Conclusion

      Summary Fig. 1

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Neveus T.
        • von Gontard A.
        • Hoebeke P.
        • Hjalmas K.
        • Bauer S.
        • Bower W.
        • et al.
        The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society.
        J Urol. 2006; 176: 314-324
        • Stein R.
        • Bogaert G.
        • Dogan H.S.
        • Hoen L.
        • Kocvara R.
        • Nijman R.J.M.
        • et al.
        EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment.
        Neurourol Urodyn. 2020; 39: 45-57
        • Kroll P.
        Pharmacotherapy for pediatric neurogenic bladder.
        Paediatr Drugs. 2017; 19: 463-478
        • Austin P.F.
        • Bauer S.B.
        • Bower W.
        • Chase J.
        • Franco I.
        • Hoebeke P.
        • et al.
        The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society.
        Neurourol Urodyn. 2016; 35: 471-481
        • Aslan A.R.
        • Kogan B.A.
        Conservative management in neurogenic bladder dysfunction.
        Curr Opin Urol. 2002; 12: 473-477
        • Bauer S.B.
        Special considerations of the overactive bladder in children.
        Urology. 2002; 60 (; discussion 9): 43-48
        • Kaviani A.
        • Khavari R.
        Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity.
        Urol Clin. 2017; 44: 463-474
        • Tang D.H.
        • Colayco D.
        • Piercy J.
        • Patel V.
        • Globe D.
        • Chancellor M.B.
        Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity.
        BMC Neurol. 2014; 14: 74
        • Madersbacher H.
        The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts.
        Paraplegia. 1990; 28: 217-229
        • Dogan H.S.
        • Stein R.
        • Hoen L.A.
        • Bogaert G.
        • Nijman R.J.M.
        • Tekgul S.
        • et al.
        Are EAU/ESPU pediatric urology guideline recommendations on neurogenic bladder well received by the patients? Results of a survey on awareness in spina bifida patients and caregivers.
        Neurourol Urodyn. 2019; 38: 1625-1631
        • Kennelly M.J.
        • Devoe W.B.
        Overactive bladder: pharmacologic treatments in the neurogenic population.
        Rev Urol. 2008; 10: 182-191
        • Rawashdeh Y.F.
        • Austin P.
        • Siggaard C.
        • Bauer S.B.
        • Franco I.
        • de Jong T.P.
        • et al.
        International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children.
        Neurourol Urodyn. 2012; 31: 615-620
        • Toviaz (Fesoterodine)
        Full prescribing information.
        Pfizer Inc, New York, NY2021
        • Biardeau X.
        • Przydacz M.
        • Aharony S.
        • Loutochin G.
        • Campeau L.
        • Kyheng M.
        • et al.
        Early fesoterodine fumarate administration prevents neurogenic detrusor overactivity in a spinal cord transected rat model.
        PLoS One. 2017; 12e0169694
        • Kaga K.
        • Yamanishi T.
        • Kaga M.
        • Fuse M.
        • Kamasako T.
        • Ishizuka M.
        Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder.
        Int J Urol. 2020; 27: 899-904
        • McGuire E.J.
        • Woodside J.R.
        • Borden T.A.
        • Weiss R.M.
        Prognostic value of urodynamic testing in myelodysplastic patients.
        J Urol. 1981; 126: 205-209
        • Galloway N.T.
        • Mekras J.A.
        • Helms M.
        • Webster G.D.
        An objective score to predict upper tract deterioration in myelodysplasia.
        J Urol. 1991; 145: 535-537
        • Scully C.
        Drug effects on salivary glands: dry mouth.
        Oral Dis. 2003; 9: 165-176
        • Erginturk Acar D.
        • Acar U.
        • Ozdemir O.
        • Ozen Tunay Z.
        • Cavkaytar S.
        The short-term and long-term adverse ocular effects of fesoterodine fumarate.
        Cutan Ocul Toxicol. 2016; 35: 181-184
        • Toviaz® (fesoterodine fumarate
        Full prescribing information.
        Pfizer Inc, New York, NY, USA2014
        • Sekeroglu M.A.
        • Hekimoglu E.
        • Anayol M.A.
        • Tasci Y.
        • Dolen I.
        An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude.
        Int J Ophthalmol. 2016; 9: 743-745
        • Pagoria D.
        • O'Connor R.C.
        • Guralnick M.L.
        Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
        Curr Urol Rep. 2011; 12: 351-357
        • Callegari E.
        • Malhotra B.
        • Bungay P.J.
        • Webster R.
        • Fenner K.S.
        • Kempshall S.
        • et al.
        A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
        Br J Clin Pharmacol. 2011; 72: 235-246
        • Kay G.G.
        • Maruff P.
        • Scholfield D.
        • Malhotra B.
        • Whelan L.
        • Darekar A.
        • et al.
        Evaluation of cognitive function in healthy older subjects treated with fesoterodine.
        Postgrad Med. 2012; 124: 7-15
        • Kim Y.J.
        • Tae B.S.
        • Bae J.H.
        Cognitive function and urologic medications for lower urinary tract symptoms.
        Int Neurourol J. 2020; 24: 231-240
        • Malhotra B.
        • El-Tahtawy A.
        • Wang E.Q.
        • Darekar A.
        • Cossons N.
        • Crook T.J.
        • et al.
        Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder.
        J Pediatr Urol. 2012; 8: 336-342
        • Ramsay S.
        • Naud É.
        • Simonyan D.
        • Moore K.
        • Bolduc S.
        A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: the FOXY study.
        Can Urol Assoc J. 2020; 14: 192-198
        • van den Heijkant M.
        • De Coster K.
        • Jansen K.
        • Bogaert G.
        Can oral fesoterodine Be an alternative for intravesical oxybutynin instillations in children with neuropathic bladder dysfunction?.
        Urol Int. 2019; 103: 202-210